Although it appears that, in contrast to inhibition of TNF, blockade of mIL-6Rα does not account for TB progression in mice [214], human studies indicate that treatment with tocilizumab increases the risk of serious infections to a similar extent as TNF antagonists [215]. Here, TNF is linked to tuberculosis.